Abstract：Liquid biopsy is an emerging detection technique with the advantages of being less invasive, highly specific, and avoiding tumor heterogeneity and it used in early screening, efficacy assessment, and recurrence monitoring of tumors. For patients with low to intermediate locally advanced rectal cancer (LARC) receiving neoadjuvant therapy, determining the efficacy of neoadjuvant therapy and monitoring tumor recurrence determines treatment options. Several studies demonstrate that liquid biopsy can predict the effectiveness of neoadjuvant treatment in patients with LARC, monitor tumor recurrence earlier than tumor markers such as carcinoembryonic antigen and imaging, and show the long-term survival prognosis of patients, thus providing a more personalized treatment strategy for patients with LARC receiving neoadjuvant therapy. This article reviews and summarizes the use of liquid biopsy in the neoadjuvant treatment of LARC, focusing on several indicators in liquid biopsy.
赵韵琳 黄诗 柯舒慧 林丹丹. 液体活检在直肠癌新辅助治疗中的研究进展[J]. 中国医药导报, 2023, 20(30): 55-58.
ZHAO Yunlin HUANG Shi KE Shuhui LIN Dandan. Research progress of liquid biopsy in the neoadjuvant treatment of rectal cancer. 中国医药导报, 2023, 20(30): 55-58.
[1] Passardi A，Rapposelli IG，Scarpi E，et al. Neoadjuvant treatment （FOLFOX4 plus hypofractionated tomotherapy） for patients with locally advanced rectal cancer：a multicenter phase Ⅱ trial [J]. Ther Adv Med Oncol，2020，12（12）：175883592 0977139. [2] Massihnia D，Pizzutilo EG，Amatu A，et al. Liquid biopsy for rectal cancer：A systematic review [J]. Cancer Treat Rev，2019，46（79）：101893. [3] Raza A，Khan AQ，Inchakalody VP，et al. Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer [J]. J Exp Clin Cancer Res，2022，41（1）： 99. [4] Gao Y，Zhao H，An K，et al. Whole-genome bisulfite sequencing analysis of circulating tumour DNA for the detection and molecular classification of cancer [J]. Clin Transl Med，2022， 12（8）：e1014. [5] Carpinetti P，Donnard E，Bettoni F，et al. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation [J]. Oncotarget，2015，6（35）：38360-38371. [6] Boniface C，Deig C，Halsey C，et al. The Feasibility of Patient-Specific Circulating Tumor DNA Monitoring throughout Multi-Modality Therapy for Locally Advanced Esophageal and Rectal Cancer：A Potential Biomarker for Early Detection of Subclinical Disease [J]. Diagnostics （Basel），2021，11（1）：73. [7] Vidal J，Casadevall D，Bellosillo B，et al. Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer：A Biomarker Study from the GEMCAD 1402 Trial [J]. Clin Cancer Res，2021，27（10）：2890-2898. [8] Liu W，Li Y，Tang Y，et al. Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA [J]. Ebio Medicine，2022，9（78）：103945. [9] Tie J，Cohen JD，Wang Y，et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer：a prospective biomarker study [J]. Gut，2019， 68（4）：663-671. [10] Khakoo S，Carter PD，Brown G，et al. MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer [J]. Clin Cancer Res，2020，26（1）：183-192. [11] Fernández-Martos C，Pericay C，Losa F，et al. Effect of Afli- bercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma：The GEMCAD 1402 Randomized Clinical Trial [J]. JAMA Oncol，2019，5（11）：1566-1573. [12] Murahashi S，Akiyoshi T，Sano T，et al. Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy：prediction of pathological response and postoperative recurrence [J]. Br J Cancer，2020， 123（5）：803-810. [13] Wang Y，Yang L，Bao H，et al. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer：A pros- pective cohort study [J]. PLoS Med，2021，18（8）：e1003741. [14] Appelt AL，Andersen RF，Lindebjerg J，et al. Prognostic Value of Serum NPY Hypermethylation in Neoadjuvant Chemoradiotherapy for Rectal Cancer：Secondary Analysis of a Randomized Trial [J]. Am J Clin Oncol，2020，43（1）：9-13. [15] Mcduff SGR，Hardiman KM，Ulintz PJ，et al. Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer [J]. JCO Precis Oncol，2021，5（5）：PO.20.00220. [16] Zhou J，Wang C，Lin G，et al. Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer：A Prospective Multicenter Study [J]. Clin Cancer Res，2021， 27（1）：301-310. [17] Glynne-Jones R，Glynne-Jones S. The concept and use of the neoadjuvant rectal score as a composite endpoint in rectal cancer [J]. Lancet Oncol，2021，22（7）：e314-e326. [18] García-Pardo M，Makarem M，Li JJN，et al. Integrating circulating-free DNA （cfDNA） analysis into clinical practice：opportunities and challenges [J]. Br J Cancer，2022，127（4）： 592-602. [19] Schou JV，Larsen FO，S?覬rensen BS，et al. Circulating cell- free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer [J]. Ann Oncol，2018，29（3）：610- 615. [20] Ji D，Zhang D，Zhan T，et al. Tumor mutation burden in blood predicts benefit from neoadjuvant chemo/radiotherapy in locally advanced rectal cancer [J]. Genomics，2021，113（1 Pt 2）：957-966. [21] Lin D，Shen L，Luo M，et al. Circulating tumor cells：biology and clinical significance [J]. Signal Transduct Target Ther， 2021，6（1）：404. [22] Magni E，Botteri E，Ravenda PS，et al. Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery [J]. Int J Colorectal Dis ，2014，29（9）：1053-1059. [23] Hinz S，R?觟der C，Tepel J ，et al. Cytokeratin 20 positive circulating tumor cells are a marker for response after neoadjuvant chemoradiation but not for prognosis in patients with rectal cancer [J]. BMC Cancer，2015，15（15）：953. [24] Silva VSE，Abdallah EA，Flores BDT，et al. Molecular and Dynamic Evaluation of Proteins Related to Resistance to Neoadjuvant Treatment with Chemoradiotherapy in Circulating Tumor Cells of Patients with Locally Advanced Rectal Cancer [J]. Cells，2021，10（6）：1539. [25] Flores BCT，Silva VSE，Abdallah EA，et al. Molecular and Kinetic Analyses of Circulating Tumor Cells as Predictive Markers of Treatment Response in Locally Advanced Rectal Cancer Patients [J]. Cells，2019，8（7）：641. [26] Kassam Z，Burgers K，Walsh JC，et al. A prospective feasibility study evaluating the role of multimodality imaging and liquid biopsy for response assessment in locally advanced rectal carcinoma [J]. Abdom Radiol（NY），2019，44（11）：3641-3651. [27] Dreussi E，Pucciarelli S，De Paoli A，et al. Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients [J]. Oncotarget，2016， 7（15）：19781-19793. [28] Yu J，Li N，Wang X，et al. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer [J]. Oncotarget，2016，7（39）：64233-64243 . [29] Meltzer S，Bjornetro T，Lyckander LG，et al. Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer [J]. Transl Oncol ，2019，12（8）：1038- 1044. [30] Stary V，Wolf B，Unterleuthner D，et al. Short-course radiotherapy promotes pro-inflammatory macrophages via extracellular vesicles in human rectal cancer [J]. J Immunother Cancer，2020，8（2）：e000667.
2023, Vol. 20 
京公网安备 11010502046598号